Search Results - "ESAKI, T"

Direct evidence of specific localization of sesquiterpenes and marchantin A in oil body cells of Marchantia polymorpha L by Tanaka, M., Esaki, T., Kenmoku, H., Koeduka, T., Kiyoyama, Y., Masujima, T., Asakawa, Y., Matsui, K.

“…Liverworts are a rich source of a diverse array of specialized metabolites, such as terpenoids and benzenoids, which are potentially useful for pharmaceutical…”
Get full text

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) by Yamazaki, K., Nagase, M., Tamagawa, H., Ueda, S., Tamura, T., Murata, K., Eguchi Nakajima, T., Baba, E., Tsuda, M., Moriwaki, T., Esaki, T., Tsuji, Y., Muro, K., Taira, K., Denda, T., Funai, S., Shinozaki, K., Yamashita, H., Sugimoto, N., Okuno, T., Nishina, T., Umeki, M., Kurimoto, T., Takayama, T., Tsuji, A., Yoshida, M., Hosokawa, A., Shibata, Y., Suyama, K., Okabe, M., Suzuki, K., Seki, N., Kawakami, K., Sato, M., Fujikawa, K., Hirashima, T., Shimura, T., Taku, K., Otsuji, T., Tamura, F., Shinozaki, E., Nakashima, K., Hara, H., Tsushima, T., Ando, M., Morita, S., Boku, N., Hyodo, I.

“…FOLFIRI and FOLFOX have shown equivalent efficacy for metastatic colorectal cancer (mCRC), but their comparative effectiveness is unknown when combined with…”
Get full text

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials by Yoshino, T., Cleary, J.M., Van Cutsem, E., Mayer, R.J., Ohtsu, A., Shinozaki, E., Falcone, A., Yamazaki, K., Nishina, T., Garcia-Carbonero, R., Komatsu, Y., Baba, H., Argilés, G., Tsuji, A., Sobrero, A., Yamaguchi, K., Peeters, M., Muro, K., Zaniboni, A., Sugimoto, N., Shimada, Y., Tsuji, Y., Hochster, H.S., Moriwaki, T., Tran, B., Esaki, T., Hamada, C., Tanase, T., Benedetti, F., Makris, L., Yamashita, F., Lenz, H.-J.

“…The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI)…”
Get full text

Rock Joint Surfaces Measurement and Analysis of Aperture Distribution under Different Normal and Shear Loading using GIS by Sharifzadeh, M., Mitani, Y., Esaki, T.

“…Summary The geometry of the rock joint is a governing factor for joint mechanical and hydraulic behaviour. A new method for evaluating the aperture…”
Get full text

The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced esophageal cancer by Kato, K., Kojima, T., Saeki, H., Hara, H., Kajiwara, T., Hironaka, S., Nakatsumi, H., Kadowaki, S., Kagawa, Y., Esaki, T., Moriwaki, T., Kobayashi, T., Izawa, N., Nomura, S., Kuwata, T., Fujii, S., Okamoto, W., Shitara, K., Ohtsu, A., Yoshino, T.

Get full text

Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS) by Ryu, M.-H., Baba, E., Lee, K.H., Park, Y.I., Boku, N., Hyodo, I., Nam, B.-H., Esaki, T., Yoo, C., Ryoo, B.-Y., Song, E.-K., Cho, S.-H., Kang, W.K., Yang, S.H., Zang, D.Y., Shin, D.B., Park, S.R., Shinozaki, K., Takano, T., Kang, Y.-K.

“…Five-weekly S-1 plus cisplatin (SP5) is one of the standard first-line regimens for advanced gastric cancer (GC), proven in a Japanese phase III study. To…”
Get full text

Avelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial by Doi, T., Iwasa, S., Muro, K., Satoh, T., Hironaka, S., Esaki, T., Nishina, T., Hara, H., Machida, N., Komatsu, Y., Shimada, Y., Otsu, S., Shimizu, S., Chand, V., Watanabe, M.

Get full text

Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1 by Lin, C.-C., Doi, T., Muro, K., Hou, M.-M., Esaki, T., Hara, H., Chung, H.-C., Osada, M., Helwig, C., Kondo, S.

Get full text

Spatial probabilistic modeling of slope failure using an integrated GIS Monte Carlo simulation approach by Zhou, G., Esaki, T., Mitani, Y., Xie, M., Mori, J.

“…Spatial probabilistic modeling of slope failure using a combined Geographic Information System (GIS), infinite-slope stability model and Monte Carlo simulation…”
Get full text

Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study by Kawakami, T, Yamazaki, K, Oki, E, Shimokawa, M, Takahashi, N, Yokota, M, Tokunaga, S, Esaki, T, Gamoh, M, Maeda, A, Tsuji, Y, Sakai, A, Hatanaka, K, Shimada, Y, Shiozawa, M, Komatsu, Y, Okuda, H, Ohue, M, Maehara, Y

Get full text

BIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703) by Kotani, D., Bando, H., Masuishi, T., Komatsu, Y., Yamaguchi, K., Nakajima, T.E., Satoh, T., Nishina, T., Esaki, T., Nomura, S., Sakamoto, S., Iida, S., Matsuda, S., Yonemura, M., Fuse, N., Sato, A., Fujii, S., Ebi, H., Ohtsu, A., Yoshino, T.

Get full text

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer by Koizumi, W, Yamaguchi, K, Hosaka, H, Takinishi, Y, Nakayama, N, Hara, T, Muro, K, Baba, H, Sasaki, Y, Nishina, T, Fuse, N, Esaki, T, Takagi, M, Gotoh, M, Sasaki, T

“…Background: This study aimed to determine whether combination S-1 plus cisplatin (CDDP) therapy, the most widely used therapy for Japanese patients with…”
Get full text

BRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701) by Masuishi, T., Taniguchi, H., Kotani, D., Bando, H., Komatsu, Y., Yamaguchi, K., Nakajima, T.E., Satoh, T., Nishina, T., Esaki, T., Wakabayashi, M., Nomura, S., Sakamoto, S., Ono, H., Hirano, N., Fujishiro, N., Fuse, N., Sato, A., Ohtsu, A., Yoshino, T.

Get full text

Development of a shear-flow test apparatus and determination of coupled properties for a single rock joint by Esaki, T., Du, S., Mitani, Y., Ikusada, K., Jing, L.

“…A new laboratory technique for coupled shear-flow tests of rock joints was developed and used to investigate the coupled effect of joint shear deformation and…”
Get full text

The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer by Yuki, S., Kato, T., Taniguchi, H., Hamaguchi, T., Akagi, K., Denda, T., Mizukami, T., Oki, E., Yamada, T., Shiozawa, M., Kudo, T., Tamura, T., Esaki, T., Naruge, D., Kajiwara, T., Nomura, S., Fujii, S., Shitara, K., Ohtsu, A., Yoshino, T.

Get full text

Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis by M. Imai, Y. Nakamura, T. Denda, Y. Komatsu, S. Yuki, T. Nishina, Y. Hamamoto, H. Hara, T. Esaki, H. Kawakami, K. Kato, T. Satoh, N. Okano, Y. Sunakawa, H. Taniguchi, K. Yamaguchi, T. Yamada, I. Miki, M. Wakabayashi, T. Kuwata, K. Shitara, T. Yoshino

“…Background: The programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1)/programmed cell death-ligand 2 (PD-L2) axis is responsible for…”
Get full text

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR) by Okamoto, W., Sakai, K., Makiyama, A., Yamamoto, Y., Shitara, K., Denda, T., Izawa, N., Nakano, Y., Nishina, T., Esaki, T., Hara, H., Miura, Y., Boku, N., Yamazaki, K., Hironaka, S., Misumi, T., Hyodo, I., Muro, K., Nishio, K.

“…The purpose of this prospective study was to assess the ability of plasma vascular endothelial growth factor-A short isoforms (pVEGF-Asi) to predict…”
Get full text

PD-014Final survival results and onset of neutropenia as an indicator of therapeutic effect in phase 2 of TAS-102 vs placebo with metastatic colorectal cancer (J003-10040030) by Yoshino, T, Shinozaki, E, Yamazaki, K, Nishina, T, Komatsu, Y, Baba, H, Tsuji, A, Yamaguchi, K, Muro, K, Sugimoto, N, Tsuji, Y, Moriwaki, T, Esaki, T, Hamada, C, Tanase, T, Ohtsu, A

Get full text

P-171The impact on survival of CPT-11 as third-line or later treatment in advanced gastric cancer by Makiyama, A, Arimizu, K, Hirano, G, Makiyama, C, Matsushita, Y, Shirakawa, T, Ohmura, H, Komoda, M, Uchino, K, Inadomi, K, Kusaba, H, Shinohara, Y, Kuwayama, M, Kajitani, T, Esaki, T, Baba, E

Get full text

A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients by Nishina, Tomohiro, Takano, Yoshinao, Denda, Tadamichi, Yasui, Hisateru, Takeda, Koji, Ura, Takashi, Esaki, Taito, Okuyama, Yusuke, Kondo, Ken, Takahashi, Yasuo, Sugiyama, Yasuyuki, Muro, Kei

“…In Japan, there had been no prospective clinical studies conducted in terms of modified FOLFOX6 + bevacizumab therapy. We performed a post-marketing Phase II…”
Get full text